Bergamottin a CYP3A inhibitor found in grapefruit juice inhibits prostate cancer cell growth by downregulating androgen receptor signaling and promoting G0/G1 cell cycle block and apoptosis

Opalina Vetrichelvan¹, Priyatham Gorjala¹, Oscar Goodman, Jr.¹,², Ranjana Mitra¹*¹

¹ Department of Biomedical Sciences, College of Medicine, Roseman University of Health Sciences, Las Vegas, Nevada, United States of America, ² Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States of America

* rmitra@roseman.edu

Abstract

Prostate cancer is the second leading cause of cancer related death in American men. Several therapies have been developed to treat advanced prostate cancer, but these therapies often have severe side effects. To improve the outcome with fewer side effects we focused on the furanocoumarin bergamottin, a natural product found in grapefruit juice and a potent CYP3A inhibitor. Our recent studies have shown that CYP3A5 inhibition can block androgen receptor (AR) signaling, critical for prostate cancer growth. We observed that bergamottin reduces prostate cancer (PC) cell growth by decreasing both total and nuclear AR activation reducing downstream AR signaling. Bergamottin’s role in reducing AR activation was confirmed by confocal microscopy studies and reduction in prostate specific antigen (PSA) levels, which is a marker for prostate cancer. Further studies revealed that bergamottin promotes cell cycle block and accumulates G0/G1 cells. The cell cycle block was accompanied with reduction in cyclin D, cyclin B, CDK4, P-cdc2 (Y15) and P-wee1 (S642). We also observed that bergamottin triggers apoptosis in prostate cancer cell lines as evident by TUNEL staining and PARP cleavage. Our data suggests that bergamottin may suppress prostate cancer growth, especially in African American (AA) patients carrying wild type CYP3A5 often presenting aggressive disease.

Introduction

Prostate cancer (PC) is the second leading cause of cancer death in US men: according to the American Cancer Society, approximately 34,130 men will die of prostate cancer in 2021. Anti-cancer treatment often has adverse effects due to its action within normal tissues. Given the initial slow growing nature of prostate cancer and the front-line efficacy of androgen deprivation therapy (ADT), adjunctive therapy using dietary supplements with these ADT may provide us options to lower ADT dosage and reduce its adverse effects.
In this study we have tested the effects of bergamottin, a natural occurring furanocoumarin, found in grapefruit juice. Furanocoumarins are secondary metabolites produced in citrus fruits and they support a plant’s defense against pathogens [1–3]. The major furanocoumarins found in grapefruit are bergamottin, epoxybergamottin and 6’,7’ dihydroxybergamottin [4]. Furanocoumarins have been reported to have anticancer activity and are known to activate multiple signaling pathways leading to cell cycle arrest, apoptosis, and cell death [3, 5]. Bergamottin has been studied for its anti-proliferative effect on different cancer cell types as a dietary supplement [6–8].

Bergamottin, the furanocoumarin compound used in our current study, is also a strong inhibitor of CYP3A4/5, a P450 enzyme dominantly expressed in the liver [9–12]. Based on its crystal structure bergamottin shows a tendency towards π-π stacking which influences its interaction with the heme group of CYP3A4/5 [9]. CYP3A5 is the main extrahepatic P450 form expressed in both normal prostate and in prostate cancer [13]. Hence bergamottin, a CYP3A5 inhibitor, can play an important role in treating prostate cancer. The androgen receptor (AR) is the driving force of prostate cancer growth. In our previous studies we have shown that CYP3A5 expressed in intratumoral prostate regulates AR expression regulating prostate cancer cell growth [14]. We selected bergamottin for this study to monitor if it can be used as an CYP3A5 inhibitor to reduce AR activation and block prostate cancer growth.

Prostate cancer represents a major health disparity among African American (AA) men as new cases diagnosed are 60% higher in AAs as compared to Caucasian men (CA) [15, 16]. The expression of CYP3A5 is polymorphic, the most common mutant, CYP3A5 (*3), is expressed in 95% CA resulting in very low protein activity [17], AAs preferentially (74%) carry wild type (*1, form expressing full length active CYP3A5 protein) CYP3A5, which constitutively promotes AR activation potentially contributing to health disparity. CA men conversely carry the mutant form expressing very low levels of CYP3A5 protein.

As bergamottin is a CYP3A inhibitor its inhibitory effect can provide with a treatment strategy in AAs expressing high levels of CYP3A5 [18]. To test the effect of bergamottin on prostate cancer growth we used two cell lines one of AA origin (MDAPCa2b) expressing wild type CYP3A5 and the other of CA origin (LNCaP) carrying mutant CYP3A5. Bergamottin has been shown to inhibit cancer cell growth by regulating multiple pathways in different cancer types, stat3 pathway, PARP cleavage and apoptosis, PI3/Akt survival pathway, cyclinD1/cell cycle block and VEGF/angiogenesis inhibition [3, 19, 20]. So far it has not been tested for its ability to block AR activation which is very relevant in prostate cancer. In our recently published work we have shown how CYP3A5 inhibitors and inducers can alter AR activation more so in AAs expressing wild type CYP3A5 [21]. Understanding the biological mechanisms of how bergamottin regulates AR signaling in prostate cancer patients can help establish its mechanism based role in blocking prostate cancer growth especially in AAs expressing high CYP3A5 to reduce health disparity. In the current study we have examined if bergamottin can modulate the growth of the prostate cancer cells by altering AR signaling, prostate specific antigen (PSA) production, and cell cycle blockage.

### Materials and methods

#### Cell lines, drugs and antibodies

LNCaP, MDAPCa2b and RWPE1 cells were purchased from ATCC and maintained in RPMI (Invitrogen, Carlsbad, CA), F-12K medium (ATCC® 30–2004) and Keratinocyte SFM media (Invitrogen, Carlsbad, CA) respectively. Supplements were added as recommended by ATCC. We have genotyped these two cell lines used in our current study. The LNCaP carries only mutant CYP3A5 (*3/*3) where as MDAPCa2b carries one wild type and one mutant CYP3A5
producing higher levels of CYP3A5 full length protein [21]. The *3 splice variant results in a truncated protein due to the presence of a stop codon. The cell lines carrying the *3 variant can only produce some active protein (5–10% as compared to *1) by alternate splicing, bypassing the stop codon. Both the lines used in the study (LNCaP and MDAPCa2b) are androgen receptor positive and express PSA. Both LNCaP and MDAPCa2b cells are also androgen sensitive and show increased growth and higher PSA production with androgen induction. The LNCaP cells carry a mutation in the ligand binding site of AR receptor so it is able to bind promiscuously to a variety of steroids [22], whereas MDAPCa2b cells are androgen independent [23].

Antibodies against Androgen receptor (ab74272, ab133273) were obtained from Abcam, Cambridge, MA) anti-GAPDH (10R-G109A) was from Fitzgerald Industries (Acton, MA). Anti-α tubulin (2125S) and anti Lamin A/C (4C11), anti-PSA/KLK3 (D6B1) PARP (9542) and cell cycle regulation sampler kits (9932 and 9870) were obtained from Cell signaling technologies (Danvers, MA). The secondary antibodies (IR dye 680 and IR dye 800) were from LI-COR (Lincoln, NE). CYP3A inhibitor bergamottin (01338) was purchased from Sigma-Aldrich (St. Louis, MO).

MTT assay
Growth of the cells was measured using a MTT assay. Cells were plated (2000 cells/ 96 well or 13,000 cells/ 24 well) for 48 hours then treated with bergamottin for 4 days (96 hours) and then incubated with MTT (3-(4,5-Dimethylthiazol- 2-yl)-2,5-Diphenyltriazolium bromide) (4 mg/ml) for 2 h. at 37°C. DMSO (vehicle control for bergamottin) levels were compensated in each bergamottin treatment group. Cells were centrifuged at 2000 g for 10 min and the supernatant was discarded. The cell pellet was dissolved in 100/500 μl of DMSO depending on the well size. A plate reader was used to read the absorption at 540 nm. Experiments were performed in octuplet/quadruplet and repeated at least three times.

Clonogenic assay
For clonogenic assay, cells were plated in 6 well plates (10,000 cells) for 48 h and then treated with indicated amounts of bergamottin and vehicle control (DMSO). After 3 weeks, the colonies were fixed, stained (0.75% crystal violet, 50% ethanol and 1.75% formaldehyde) and counted. The assay was repeated three times.

Western blotting
Cells were plated at 25–30% confluence when maintained in complete media. When the cells required DHT treatment and media replacement to charcoal stripped serum media (CSSM) they were plated at 35–40% confluence. Bergamottin is dissolved in DMSO (vehicle control) and the amount of DMSO at each treatment group was kept constant. After the completion of the treatment cells were washed in phosphate buffer (PBS) containing 2mMEDTA and 2mM EGTA and lysed in RIPA buffer (50 mM TRIS, 150 mM NaCl, 1% NP40, 0.5% sodium deoxycholate, 0.1% SDS, 2mM EDTA, 2mM EGTA) supplemented with protease and phosphatase inhibitors for total protein isolation. Protein estimation was performed using micro BCA assay and equal protein amounts were loaded on SDS-PAGE gels for western analysis. GAPDH was used as an internal control for total protein. Infrared fluorescent-labeled secondary antibodies were used for detection using Odyssey CLx. The bands were quantified using Odyssey software, which calculates pixel density and automatically takes an area adjacent to each band for background corrections.
**Cell fractionation**

Nuclear and cytoplasmic cell fractionation was prepared using NE-PER Nuclear and cytoplasmic extraction kit from Thermo Scientific (Cat no.78833) and manufacturer’s instructions were followed. When the cells were treated with DHT, the media was changed to charcoal stripped serum media without phenol red (CSSM) 48 hours prior to the treatment. Bergamottin and DHT were added at specified concentration and duration as indicated. Cells were washed in PBS once before cells were suspended in CER buffer. Protease, phosphatase inhibitors and EDTA was added prior to cell lysis. The pellet remaining after cytoplasmic isolation was washed twice with PBS. The pellet was suspended in NER buffer for nuclear fraction extraction according to guidelines, samples were stored at -80˚C until further processing. Tubulin and Lamin were used as internal controls for cytoplasmic and nuclear fractions respectively.

**Confocal microscopy**

Cells were seeded into 35 mm Glass bottom dish (Cellvis catalog# D35C4-20-1.5-N) in complete media; media was changed to CSSM prior to DHT treatment. The cells were fixed in 4% paraformaldehyde for 20 minutes and permeabilized using permeabilizing buffer (0.2% Tween 20 in PBS) for 5 minutes. Cells were blocked using 10% goat serum diluted in permeabilizing buffer with 1% BSA for 15 minutes. Primary antibodies were diluted at 1:100 in staining buffer (1% BSA in PBS) and incubated for 2 hours at room temperature. Cells were washed three times (5 minutes each) in PBS. Secondary antibodies, TRITC-conjugated Donkey Anti-rabbit (711-025-152) was from Jackson immuno research, West Grove, PA was diluted at 1:100 in staining buffer and incubated for 60 minutes at room temperature. Cells were washed three times (5 minutes) in PBS and stained with 1 μg/mL DAPI (4’, 6-diamidino-2-phenylindole) in PBS for 5 minutes at room temperature. The cells were stored in PBS at 4˚C until imaging was completed.

Cells were imaged using confocal laser scanning microscopy on a Nikon A1R using a galvano scanner and a 60× Apo-TIRF oil immersion objective. NIS Elements software form Nikon was used for recording the data.

**SiRNA transfection**

Cells were plated in complete media without antibiotics on poly D-lysine-coated plates (80,000 cells per 6 well). After 48 hrs. of plating cells were transfected with smart pool non-target (NT) control siRNA (Dharmacon catalog# D-001810-10) and a pool of four siRNA (Dharmacon catalog# L-009684-01) against the CYP3A5 using RNAimax, manufacturer’s instructions were followed. The final concentration of the siRNA (NT and target) used was 30 nM. The cells were processed for cell cycle and western analysis 96 hours after the transfection.

**Cell cycle assay and analysis**

Cell cycle analysis was performed after staining the cells with propidium iodide (PI). For long term bergamottin treatment (96 hrs.) cells were plated at 25–30% confluence and for short term bergamottin treatment (48 hrs.) they were plated at 30–35% confluence. After completion of specified treatment the cells were trypsinized washed with PBS and fixed in 70% ethanol and then stained with PI in nicoletti buffer (propidium iodide 50 μg/ml, 0.1% sodium citrate, 0.1% triton X-100, RNase 1 mg/ml, in DPBS). Cells were analyzed using C6 Accuri flow cytometer (Becton Dickinson, Mountainview, CA). FlowJo software was used to gate and remove the debris (gate on SSC and FSC) and aggregates (FL2 A and FL2H) from the analysis. Watson pragmatic and and Dean-Jett -Fox methods was used to assign percentage frequencies to cells present in the different cell cycle stages.
Apoptosis detection assay

To detect apoptosis in the cells after bergamottin treatment In Situ cell death detection kit from Sigma-Aldrich (St. Louis, MO) was used. This apoptosis detection kit fluorescently labels the single and double-stranded DNA breaks caused due to apoptosis using terminal deoxynucleotidyl transferase (TUNEL-reaction). The cells were plated in poly-D-lysine coated 35 mm Glass bottom dish (Cellvis catalog# D35C4-20-1.5-N), treated with bergamottin for the specified time, and dosage and then stained with the kit reagents. The kit recommended protocol was followed. After the staining, the confocal microscope was used to procure images of the cells. The TUNEL assay preferentially labels apoptosis in comparison to necrosis and positive apoptosis is recognized when cells incorporate fluorescent labelled nucleotide (Ex 450 to 500nm and Em 515 to 565-green).

Results

Bergamottin blocks growth of prostate cancer cell lines

We tested the effects of bergamottin on prostate cancer cells using MTT and clonogenic assays. Since bergamottin is, a known CYP3A inhibitor we used two separate prostate cancer cell lines to test its effect differentially: LNCaP, of Caucasian origin carrying mutant CYP3A5 and expressing low CYP3A5, and MDAPCa2b, of African American origin and carrying one wild type CYP3A5 and expressing higher levels of CYP3A5 active protein. MTT assay revealed that bergamottin reduced prostate cancer cell growth. The 50% growth reduction was observed in LNCaP and MDAPCa2b cells with 2.4 μM and 4 μM bergamottin treatment respectively (Fig 1A). Growth assay also revealed that bergamottin does not effect growth of RWPE1 cells (non transformed prostate epithelium) at lower concentration although at higher concentration (10μM) all the three cell lines show 60% inhibition of growth. The growth inhibition effect of bergamottin was further confirmed using long term clonogenic assays. Bergamottin significantly reduced the number of colonies in both the cell lines, LNCaP and MDAPCa2b, at both 5μM and 10μM concentrations (Fig 1B).

Bergamottin reduces androgen expression, AR activation and PSA production

Androgen receptor is the driving force of prostate cancer growth. Since we observed that bergamottin blocked prostate cancer cell growth, we tested its effect on AR expression and

![Fig 1. Bergamottin blocks prostate cancer cell growth.](https://doi.org/10.1371/journal.pone.0257984.g001)
Bergamottin downregulated total AR levels in both LNCaP and MDAPCa2b cells by 50% (Fig 2A). DHT slightly increased the total AR expression in DMSO and bergamottin treated LNCaP and MDAPCa2b cells. Cell fractionation experiments with LNCaP cells showed that bergamottin inhibited nuclear translocation of AR consistent with CYP3A5 siRNA inhibition reported earlier: nuclear AR with and without DHT induction was lower in the bergamottin treated cells compared to the control set (Fig 2B). The inhibition of nuclear translocation of AR was further confirmed in both the cell lines using confocal microscopy studies (Fig 2C and 2D). In bergamottin treated cells, active AR migration to the nucleus with DHT induction was significantly reduced versus the control (DMSO) treated cells. Interestingly, we observed this pattern of increased cytoplasmic AR in our confocal images with bergamottin similar to other inhibitor treatments (e.g. ritonavir, [21]) observed earlier. Bergamottin also significantly
reduced PSA levels in both cell lines which is a readout for AR downstream signaling as PSA expression is regulated by AREs (androgen response elements) (Fig 2E).

**Bergamottin induces cell cycle arrest**

Since bergamottin reduces cell growth we tested its effect on the cell cycle. The cells were treated with either higher concentration (20μM and 30μM) of bergamottin for a shorter duration (48 hours) (Fig 3A) or lower concentration (5μM and 10μM) of bergamottin for longer duration (96 hours) (Fig 3B). It has been shown earlier that the IC₅₀ for Bergamottin CYP3A5 inhibition is 20μM [11], to compensate for the shorter time (48 hrs.) of treatment we have increased the dosage in line with the Ki value. Cell cycle analysis revealed accumulation of cells in the G0/G1 phase in both high and low dose treatment groups in both the cell lines tested (Fig 3A and 3B, Table 1). With 30μM (48 hrs.) and 10μM (96 hrs.) bergamottin treatment we also observed significant reduction of S-phase cells as compared to the control (Fig 3A and 3B). Both the analysis methods Watson pragmatic and Dean-Jett-Fox show accumulation of cells in the G0/G1 phase and reduction in S phase cells in both LNCaP and MDAPCa2b cells with one exception (LNCaP 96 hrs treatment Dean-Jett-Fox analysis). Inhibition of CYP3A5 using an CYP3A5 siRNA pool also showed same accumulation of G0/G1 population and depletion of S phase cells in both the cell lines (Fig 3C and Table 1) with both analyses. Both

![Fig 3. Bergamottin treatment causes accumulation of G0/G1 cells similar to CYP3A5 siRNA treated cells.](https://doi.org/10.1371/journal.pone.0257984.g003)
Table 1. Cell cycle analysis showing effect of bergamottin and CYP3A5 siRNA treatment in LNCaP and MDAPCa2b cells.

|                  | LNCaP (48 hrs. bergamottin treatment) |          | Watson Pragmatic |          |
|------------------|--------------------------------------|----------|------------------|----------|
|                  | G1        | S        | G2       | G1        | S        | G2       |
| DMSO             | 75.7 ±3.2| 9.7 ±4.8 | 11.8 ±0.7| DMSO      | 96.5 ±8.9| 7.5 ±1.3 | 10.6 ±0.9|
| Berg (20µM)      | 86.7 ±2.3| -9.8 ±3.0| 15.3 ±1.0| Berg (20µM)| 119.7 ±4.6| 4.8 ±3.5 | 13.4 ±4.3|
| Berg (30µM)      | 96.2 ±3.6| -8.4 ±4.5| 7.7 ±0.9 | Berg (30µM)| 134.7 ±3.2| 3.7 ±2.6 | 6.3 ±2.3 |

|                  | LNCaP (96 hrs. bergamottin treatment) |          | Watson Pragmatic |          |
|------------------|--------------------------------------|----------|------------------|----------|
|                  | G1        | S        | G2       | G1        | S        | G2       |
| DMSO             | 83.7 ±0.8| 1.23 ±0.8| 14.5 ±0.6| DMSO      | 85.51 ±1.2| 7.6 ±1.3 | 10.14 ±2.4|
| Berg (5µM)       | 90.81 ±7  | -0.3 ±2.3| 10.53 ±1.0| Berg (5µM)| 131.37 ±25| 0.32±4.3 | 8.59 ±3.0|
| Berg (10µM)      | 95.1 ±3.4| -0.03 ±1.1| 0.22 ±0.4| Berg (10µM)| 138.39 ±15| -1.17±4.5| 10.07 ±0.9|

|                  | MDAPCa2b (48 hrs. bergamottin treatment) |          | Watson Pragmatic |          |
|------------------|--------------------------------------|----------|------------------|----------|
|                  | G1        | S        | G2       | G1        | S        | G2       |
| DMSO             | 76.8 ±1.9| 11.4 ±1.7| 10.5 ±1.3| DMSO      | 113.2 ±5.8| 9.8 ±1.8 | 9.2 ±2.5 |
| Berg (20µM)      | 84.9 ±0.4| 6.7 ±0.7 | 9.6 ±0.5 | Berg (20µM)| 122.5 ±3.7| 7.1 ±1.7 | 9.6 ±1.8 |
| Berg (30µM)      | 88.4 ±3.6| 3.3 ±3.4 | 6.8 ±3.2 | Berg (30µM)| 135.5 ±3.0| 5.6 ±0.5 | 8.4 ±1.1 |

|                  | MDAPCa2b (96 hrs. bergamottin treatment) |          | Watson Pragmatic |          |
|------------------|--------------------------------------|----------|------------------|----------|
|                  | G1        | S        | G2       | G1        | S        | G2       |
| DMSO             | 81.3 ±1.9| 12.7 ±1.7| 3.6 ±2.6 | DMSO      | 80.2 ±11.2| 12.9 ±3.3| 8.8 ±2.4 |
| Berg (5µM)       | 84.2 ±1.5| 12.2 ±1.0| 2.3 ±2.2 | Berg (5µM)| 118.0 ±19.7| 7.7 ±2.6 | 8.4 ±1.6 |
| Berg (10µM)      | 88.8 ±2.8| 7.4 ±2.5 | 3.3 ±0.3 | Berg (10µM)| 117.6 ±8.5| 5.8 ±2.8 | 6.6 ±1.2 |

|                  | LNCaP (siRNA treatment) |          | Watson Pragmatic |          |
|------------------|------------------------|----------|------------------|----------|
|                  | G0/G1       | S        | G2/M     | G0/G1       | S        | G2/M     |
| NT siRNA         | 66.7±0.6   | 15.2±3.2| 18.3±3.1 | NT siRNA    | 88.2±0.7 | 14.1±0.4 | 19.9±0.5 |
| CYP3A5 siRNA     | 81.6±0.8   | 12.4±2.5| 2.8±3.2  | CYP3A5 siRNA| 129.8±8 | 12.6±2.3 | 13.7±2.8 |

|                  | MDAPCa2b (siRNA treatment) |          | Watson Pragmatic |          |
|------------------|---------------------------|----------|------------------|----------|
|                  | G0/G1       | S        | G2/M     | G0/G1       | S        | G2/M     |
| NT siRNA         | 75.8±1.5   | 11.3±6   | 9±8.5    | NT siRNA    | 101.4±0.9| 2.3±5.6  | 12.2±1.1 |
| CYP3A5 siRNA     | 89.9±6.7   | 8.3±4.5  | 2.0±1.9  | CYP3A5 siRNA| 118.7±8.3| 4.1±12.9 | 7±2.7    |

Table showing increase in G0/G1 population and decrease in S phase cells with bergamottin and CYP3A5 siRNA treatment in both cell lines using both cell cycle analysis methods: Dean-Jett-Fox and Watson pragmatic. The values represent average of minimum of three independent experiments, ± indicates SD values. The values written in bold indicate P value of less than 0.05 when compared with respective controls.

https://doi.org/10.1371/journal.pone.0257984.1001

bergamottin treatment and CYP3A5 siRNA treatment show a similar accumulation of G0/G1 population and depletion of S phase cells, consistent with inhibition of CYP3A5 by bergamottin.

Western blot analysis showing differential expression of cell cycle regulating proteins after bergamottin treatment

Cell cycle arrest occurs due to block at one of the four check points: G1/S check point, G2/M check point, SAC check point, intra S check point and restriction point (reversible). All these check points are regulated by cyclins and CDKs, we tested the effect of bergamottin on these
cell cycle regulating proteins. We first tested effects of bergamottin (20 and 30 μM) on cyclins and CDKs and then on proteins regulating cyclins and CDKs. Our western blot analysis revealed reduction of cyclins B1, D1, D3 and E in LNCaP cells and reduction of cyclins A, B1 and D3 in MDAPCa2b cells (Fig 4A, Table 2). We observed reduction of CDK4 and CDK6 in LNCaP and only CDK4 in MDAPCa2b cells. The fold changes after GAPDH calibration are shown in Table 2. The effect on the cyclin B1, D and CDK4 and CDK6 were tested with low concentration bergamottin treatment (5 and 10 μM) as they were altered with higher doses of bergamottin. Our results indicate that similar to high dose treatment, cyclin B1 and D3 levels were lower with low dose bergamottin treatment in both lines and cyclin D1 were lower only in LNCaP cells (Fig 4B). We did not observe any significant change in CDK4 or CDK6 levels with low dose of bergamottin in both the cell lines. We also tested the effect of CYP3A5 inhibition using siRNA on cyclins and CDKs regulating cell cycle, we observed that cyclin B, D1 and D3 were down regulated in LNCaP similar to bergamottin treatment (Fig 4C). In MDAPCa2b cells we observed down regulation of cyclin B1 and D1 which was slightly different than the pattern observed with bergamottin treatment (cyclin B1 and D3). Both CDK4 and 6 were downregulated in LNCaP cells where as only CDK6 was down regulated in MDAPCa2b cells with CYP3A5 siRNA treatment compared to NT control.

Additionally, we observed increase in p27kip1 expression in both cell lines and no changes were observed in p21 levels. Decreased phosphorylation of cdc-2 (Y15) and wee-1 (S642) were also observed in both cell lines (Fig 4A). Decreased cdc-2 phosphorylation was observed with low dose bergamottin treatment and also with CYP3A5 siRNA inhibition in both the cell lines.

Fig 4. Differential regulation of cell cycle regulating protein after bergamottin treatment. (A &B) Western blot analysis of control and bergamottin treated cells depicting changes in cell cycle regulating proteins. Treatment was either given for 48 hrs. (high dose, 20 and 30μM) or 96 hrs. (low dose, 5 and 10μM) as described in Fig 3A and 3B. (C) the effect of CYP3A5 siRNA on cell cycle regulating proteins as compared to NT (non-target) control siRNA pool treatment (96 hours). GAPDH has been used as a loading control. The experiment was repeated three times, a representative replicate is shown.

https://doi.org/10.1371/journal.pone.0257984.g004
Changes in phosphorylation of Histone H3 (S10) and Myt1 levels differed between the two cell lines with bergamottin treatment. Bergamottin causes cell death by triggering apoptosis in the cells. Our results indicates that bergamottin inhibits growth in both LNCaP and MDAPCa2b cells at significantly low concentrations (50% inhibition, 2.4 and 4μM respectively). Previously we have used CYP3A5 siRNA treatment to show CYP3A5s effect on growth using viable cell count, MTT, and clonogenic assays [14, 21]. Bergamottin has been shown to reduce growth of several other cancer cell types but the IC₅₀ were reported in the range of 30–100μM [19, 20, 24–32]. The clonogenic assays also show significant loss of growth at 5 and 10 μM concentrations. This may be because both the cells express CYP3A5 active protein and bergamottin is a potent CYP3A5 inhibitor. We do observe that bergamottin inhibits LNCaP cells at lower concentrations as compared to MDAPCa2b. This may be attributed to lower levels of CYP3A5.
protein expressed in LNCaP due to $3^\prime/3$ mutation present as compared to MDAPCa2b which carries one copy of wild type of CYP3A5 ($1^\prime/3$) [21]. Compared to LNCaP, MDAPCa2b may need higher concentration of bergamottin, due to expression of higher quantity of active full length CYP3A5 protein, to cause comparable growth inhibition. The other major difference between the previously reported results in the DU145 AR negative prostate cancer cell line [19] suggests bergamottin’s action is CYP3A5—AR signaling dependent [14]. Bergamottin does not effect RWPE1 (non-transformed prostate epithelium) cells at lower concentrations as much as it does the other two cancer cell lines which is consistent with the earlier reported data [19].

Although primarily bergamottin is a CYP3A4 inhibitor it also inhibits CYP3A5, CYP2B6 and CYP1A1 [9, 11, 12, 33, 34]. Expression of P450 CYPs is tissue specific and CYP3A5 is the major isoform expressed in both normal and prostate tumor [13]. Since CYP3A5 is the major P450 CYP isoform expressed in the prostate tissue, the effects observed in our experiments is primarily due to inhibition of CYP3A5 in the tested prostate cancer cell lines [13, 35]. The other major extrahepatic P450 isoform expressed in normal and prostate tumor is CYP1A1 [36], bergamottin is a competitive inhibitor of CYP1A1 and can aid in cancer chemoprevention due to CYP1A1s role in carcinogenesis, this inhibitory effect is independent of bergamottins affect on CYP3A5 and AR [33]. CYP3A4 and CYP2B6 are also inhibited by bergamottin but are not expressed in normal and prostate tumor cells.

Previously we have shown that CYP3A5 siRNA pool treatment blocks AR nuclear translocation [14] and had no response to growth with DHT induction which is dependent on AR nuclear translocation. Bergamottin which is a CYP3A inhibitor [6, 10, 37] also shows reduced
nuclear AR consistent with our earlier results. In addition, we have also shown how the cell growth is inhibited by azamulin, a CYP3A4/5 inhibitor similar to bergamottin. Although AR expression is not increasing in the nucleus our confocal studies show increased cytoplasmic AR with bergamottin treatment compared to control. We have previously observed similar increase in cytoplasmic AR with certain inhibitor treatments (ritonavir) [21]. We believe that AR is getting trapped in the tubulin channels and not getting recycled normally, additional studies e.g. tubulin colocalization will be needed to fully understand this observation. In addition to reduced nuclear AR, bergamottin also lowers total AR expression which may be further contributing to growth inhibition, as AR is known to be the driver of prostate cancer growth. We observed loss of PSA in the bergamottin treated cells, with PSA levels representing a downstream readout of AR signaling [38]. In our recent publication we have demonstrated that CYP3A5 inducers promote AR nuclear translocation and PSA expression where as CYP3A5 inhibitors reduce AR nuclear migration and PSA expression [21]. Simultaneous treatment with CYP3A5 siRNA pool and CYP3A5 inducer nullified increased AR translocation and PSA when compared to CYP3A5 inducer treatment alone showing that the increased AR nuclear translocation and PSA production are specific to changes in CYP3A5. PSA expression is AR dependent since Psa carries AREs (androgen response elements) upstream and responds to androgen induction. This observation can be useful in patients with high AR and CYP3A5 expression such as African Americans, who preferentially carry wild type CYP3A5 and express higher AR, accompanied by relatively aggressive disease.

Our experiments show accumulation of cells in the G0/G1 phase (low and high dose of bergamottin) and depletion of S phase cells with both high and low dose bergamottin treatment. We do observe that the effect on cell cycle is more pronounced in LNCaP cells as compared to MDAPCa2b cells, this may be due to presence of high levels of CYP3A5 in MDAPCa2b cells that may require higher dosage of bergamottin for inhibition. Similar accumulation of G0/G1 cells were observed with CYP3A5 siRNA pool treatment as compared to NT pool (Fig 3C). Since bergamottin is a CYP3A5 inhibitor; simultaneous inhibition with CYP3A5 siRNA pool and bergamottin treatment cannot decipher if the cell cycle block is due to bergamottin’s effect on AR nuclear translocation or is independent.

Accumulation of G0/G1 cells can occur at the restriction point or at the G1/S check point [39]. The restriction point is regulated by cyclin D and CDK4,6 [40]. Since we observed reduction in Cyclin D1, D3 and CDK 4,6 in LNCaP cells and Cyclin D3 and CDK4 in MDAPCa2b cells (Fig 4A, Table 2) it shows that the block is at the restriction point in both the cell lines. The decreased expression of the cyclins is consistent in both the lines even with the lower dose of bergamottin treatment (Fig 4B). Reduction in Cyclin B1, D1 D3 in LNCaP and cyclin B1, D1 in MDAPCa2b and reduction in CDK4 levels (both lines) were observed with CYP3A5 siRNA treatment resulting in G0/G1 accumulation similar to bergamottin treatment. Additionally, we observed increase in p27kip1 which indicates increased population of quiescent cells (G0). Cyclin E and CDK2 are known to regulate G1/S check point which also leads to accumulation of G0/G1 cells, which is consistent with larger block observed in LNCaP cells which show downregulation of cyclin E2. Additionally, in LNCaP both Cyclin D1 and D3 are down regulated and in MDAPCa2b only Cyclin D3 is, which explains more pronounced accumulation of G1 cells in LNCaP as compared to MDAPCa2b. We also observed slight reduction in Cyclin A in bergamottin treated MDAPCa2b cells, cyclin A levels increase in S phase and is associated with intra S check point which can explain the why the loss of S phase cells is not evident in MDAPCa2b cells as compared to LNCaP. Both the cell lines showed reduced expression of cyclin B after bergamottin treatment which is associated with G2/M check point. Although we observe changes in the cyclin B but our cell cycle analysis does not show any increase in G2/M cell population. We observed decreased phosphorylation of cdc-2 (Y15) in
Bergamottin treated cells, phosphorylation at Y15 is known to block mitotic entry. It is possible that the reduction in cyclin B and cdc-2 dephosphorylation cancel each other out and we do not see any accumulation of G2/M cells [41]. We observed less phosphorylation of wee-1 (S642) which is a Y15 kinase consistent with the loss of phosphorylation of cdc-2. There is loss of phosphorylation of Histone H (S10) in the 30uM bergamottin treated LNCaP cells which is essential for chromosomal condensation for segregation during mitosis. Bergamottin has been shown to increase sub-G1 population in myeloma cells and cause G2/M block in lung cancer cells at higher concentrations [19, 20].

Bergamottin induces apoptosis in both prostate cancer cell lines, evidenced by tunnel assay staining of late apoptotic cells by labeling DNA breaks and nicks by Terminal deoxynucleotidyl transferase, which incorporates fluorescein UTP at 3’-OH ends in a template independent manner. Tunnel assay preferentially labels DNA strand breaks generated during apoptosis which allows discrimination of apoptosis from necrosis. Both the cell lines show apoptosis after bergamottin treatment, although MDAPCa2b cells have more fluorescein UTP incorporation than in LNCaP cells. Due to the discrepancy of tunnel staining between both the cell lines PARP cleavage was investigated. We observed PARP- cleavage, an hallmark of apoptosis, with both bergamottin and CYP3A5 siRNA treatment [42]. The irreversible binding of small cleaved PARP protein is known to prevents DNA repair.

Several anticancer drugs target androgen receptor signaling to prevent tumor growth. Our observation that bergamottin, a natural furanocoumarin found in grapefruit juice, also blocks the androgen receptor expression and activation is very significant as it can be used as a dietary supplement to prevent prostate cancer growth. Previously we have investigated how CYP3A5 inhibitors and inducers can modify AR signaling and effect the efficacy of commonly prescribed concomitant medications [21]. CYP3A4/5 are hepatic enzymes and are involved in processing several commonly prescribed drugs, we do have to be cautious of drug-drug interactions while using bergamottin as an anticancer agent as it is a strong CYP3A inhibitor. Use of bergamottin on the other hand can be very significant for African Americans, who often present aggressive disease, have high AR expression [43, 44], and often carry wild type CYP3A5 [45–47]. Both, the relative incidence and mortality rate are much higher (1.8 and 2.2 times more respectively) in AAs as compared to Caucasian Americans (CA) [16]. Since bergamottin is a natural CYP3A5 inhibitor, combining it with other cancer drugs may provide an opportunity to increase efficacy of treatment, especially in AAs expressing high levels of CYP3A5.

Conclusions

Bergamottin, a potent CYP3A inhibitor blocks prostate cancer cell growth by inhibiting AR expression, nuclear localization, and PSA production. In addition, it promotes an accumulation of G0/G1 cells causing cell cycle arrest possibly leading to apoptosis and cell death. These observations suggest the potential for bergamottin to be tested as a dietary supplement for prostate cancer prevention and treatment.

Supporting information

S1 Raw images. Full blot of western gels shown in Figs 2, 4 and 5. The dotted lines show places were the blots were cut to treat with separate antibodies. During loading sometime, the markers are not next to the samples, in those cases the representative marker is placed next to the blot. (PDF)
S1 Fig. Uncropped confocal images of Fig 2C and 2D. A z-Stack passing through the middle of the nucleus showing uncropped images corresponding to Fig 2C (LNCaP) and 2D (MDAP-Ca2b). (TIF)

Author Contributions

Conceptualization: Oscar Goodman, Jr., Ranjana Mitra.
Data curation: Opalina Vetrichelvan, Priyatham Gorjala, Ranjana Mitra.
Formal analysis: Ranjana Mitra.
Funding acquisition: Ranjana Mitra.
Investigation: Opalina Vetrichelvan, Priyatham Gorjala, Oscar Goodman, Jr., Ranjana Mitra.
Methodology: Opalina Vetrichelvan, Priyatham Gorjala.
Project administration: Ranjana Mitra.
Resources: Ranjana Mitra.
Software: Opalina Vetrichelvan, Priyatham Gorjala.
Supervision: Ranjana Mitra.
Validation: Opalina Vetrichelvan, Ranjana Mitra.
Visualization: Opalina Vetrichelvan, Priyatham Gorjala, Oscar Goodman, Jr., Ranjana Mitra.
Writing – original draft: Opalina Vetrichelvan, Ranjana Mitra.
Writing – review & editing: Oscar Goodman, Jr., Ranjana Mitra.

References

1. Brown SA. Biosynthesis of the Coum arins. Vi. Further Studies on Herniarin Formation in Lavender. Can J Biochem. 1965; 43:199–207. https://doi.org/10.1139/o65-027 PMID: 14325970
2. Brown SA, Towers GH, Wright D. Biosynthesis of the coumarins. Tracer studies on coumarin formation in Hierochloe odorata and Melilotus officinalis. Can J Biochem Physiol. 1960; 38:143–56. PMID: 13805037
3. Hung WL, Suh JH, Wang Y. Chemistry and health effects of furanocoumarins in grapefruit. J Food Drug Anal. 2017; 25(1):71–83. https://doi.org/10.1016/j.jfda.2016.11.008 PMID: 28911545
4. Dugrand-Judek A, Olry A, Hehn A, Costantino G, Ollitrault P, Froelicher Y, et al. The Distribution of Coumarins and Furanocoumarins in Citrus Species Closely Matches Citrus Phylogeny and Reflects the Organization of Biosynthetic Pathways. PLoS One. 2015; 10(11):e0142757. https://doi.org/10.1371/journal.pone.0142757 PMID: 26558757
5. Ahmed S, Khan H, Aschner M, Mirzae H, Kupeli Akkol E, Capasso R. Anticancer Potential of Furanocoumarins: Mechanistic and Therapeutic Aspects. Int J Mol Sci. 2020; 21(16). https://doi.org/10.3390/ijms21165622 PMID: 32781533
6. Ko JH, Artuso F, Sethi G, Ahn KS. Pharmacological Utilization of Bergamottin, Derived from Grapefruits, in Cancer Prevention and Therapy. Int J Mol Sci. 2018; 19(12). https://doi.org/10.3390/ijms19124048 PMID: 30598157
7. Le Goff-Klein N, Klein L, Herin M, Koffel JC, Ubeaud G. Inhibition of in-vitro simvastatin metabolism in rat liver microsomes by bergamottin, a component of grapefruit juice. J Pharm Pharmacol. 2004; 56 (8):1007–14. https://doi.org/10.1211/0022357044012 PMID: 15285845
8. Sun S, Phrutivorapongkul A, Dibwe DF, Balachandran C, Awale S. Chemical Constituents of Thai Citrus hystrix and Their Antiausterity Activity against the PANC-1 Human Pancreatic Cancer Cell Line. J Nat Prod. 2018; 81(8):1877–83. https://doi.org/10.1021/acs.jnatprod.8b00405 PMID: 30079833
9. Rossi M, Aktar S, Davis M, Hefer Feuss E, Roman-Holba S, Wen K, et al. The Grapefruit Effect: Interaction between Cytochrome P450 and Coumarin Food Components, Bergamottin, Fraxidin and
Osthole. X-ray Crystal Structure and DFT Studies. Molecules. 2020; 25(14). https://doi.org/10.3390/molecules25143158 PMID: 32664320

10. He K, Iyer KR, Hayes RN, Sinz MW, Woolf TF, Hollenberg PF. Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice. Chem Res Toxicol. 1998; 11(4):252–9. https://doi.org/10.1021/tr970192k PMID: 9548795

11. Lin HL, Kent UM, Hollenberg PF. The grapefruit juice effect is not limited to cytochrome P450 (P450) 3A4: evidence for bergamottin-dependent inactivation, heme destruction, and covalent binding to protein in P450s 2B6 and 3A5. J Pharmacol Exp Ther. 2005; 313(1):154–64. https://doi.org/10.1124/jpet.104.079608 PMID: 15608076

12. Kent UM, Lin HL, Noon KR, Harris DL, Hollenberg PF. Metabolism of bergamottin by cytochromes P450 2B6 and 3A5. J Pharmacol Exp Ther. 2006; 318(3):992–1005. https://doi.org/10.1124/jpet.105.099887 PMID: 16785317

13. Molianen AM, Hakkola J, Vaarala MH, Kauppila S, Hirvikoski P, Vuorio JT, et al. Characterization of androgen-regulated expression of CYP3A5 in human prostate. Carcinogenesis. 2007; 28(5):916–21. https://doi.org/10.1093/carcin/bgl222 PMID: 17116727

14. Mitra R, Goodman OB. CYP3A5 regulates prostate cancer cell growth by facilitating nuclear translocation of AR. Prostate. 2015; 75:527–38. https://doi.org/10.1002/pros.22940 PMID: 25586052

15. Schatten H. Brief Overview of Prostate Cancer Statistics, Grading, Diagnosis and Treatment Strategies. Adv Exp Med Biol. 2018; 1095:1–14. https://doi.org/10.1007/978-3-95963-0_1 PMID: 30229546

16. DeSantis CE, Miller KD, Goding Sauer A, Jemal A, Siegel RL. Cancer statistics for African Americans, 2019. CA Cancer J Clin. 2019; 69(3):211–33. https://doi.org/10.3322/caac.21555 PMID: 30762872

17. Lamba JK, Lin YS, Schuetz EG, Thummel KE. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev. 2002; 54(10):1271–94. https://doi.org/10.1016/S0169-409X(02)00066-2 PMID: 12406645

18. Alzahrani AM, Rajendran P. The Multifarious Link between Cytochrome P450s and Cancer. Oxid Med Cell Longev. 2020; 2020:3028387. https://doi.org/10.1155/2020/3028387 PMID: 31996435

19. Kim SM, Lee JH, Sethi G, Kim C, Baek SH, Nam D, et al. Bergamottin, a natural furanocoumarin obtained from grapefruit juice induces chemosensitization and apoptosis through the inhibition of STAT3 signaling pathway in tumor cells. Cancer Lett. 2014; 354(1):153–63. https://doi.org/10.1016/j.canlet.2014.08.002 PMID: 25130160

20. Wu HJ, Wu HB, Zhao YQ, Chen LJ, Zou HZ. Bergamottin isolated from Citrus bergamia exerts in vitro and in vivo antitumor activity in lung adenocarcinoma through the induction of apoptosis, cell cycle arrest, mitochondrial membrane potential loss and inhibition of cell migration and invasion. Oncol Rep. 2016; 36(1):324–32. https://doi.org/10.3892/or.2016.4833 PMID: 27222242

21. Gorjala P, Kittles RA, Goodman OB Jr., Mitra R. Role of CYP3A5 in Modulating Androgen Receptor Signaling and Its Relevance to African American Men with Prostate Cancer. Cancers (Basel). 2020; 12(4).

22. Veldscholte J, Berrevoets CA, Ris-Stalpers C, Kuiper GG, Jenster G, Trapman J, et al. The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens. J Steroid Biochem Mol Biol. 1992; 41(3–8):665–9. https://doi.org/10.1016/0960-0760(92)90401-4 PMID: 15625539

23. Navone NM, Olive M, Ozen M, Davis R, Troncoso P, Tu SM, et al. Establishment of two human prostate cancer cell lines derived from a single bone metastasis. Clin Cancer Res. 1997; 3(12 Pt 1):2493–500. PMID: 9815652

24. Kawaii S, Tomono Y, Katase E, Ogawa K, Yano M. Isolation of furanocoumarins from bergamot fruits as HL-60 differentiation-inducing compounds. J Agric Food Chem. 1999; 47(10):4073–8. https://doi.org/10.1021/jf990155u PMID: 10552768

25. Liu Y, Ren C, Cao Y, Wang Y, Duan W, Xie L, et al. Characterization and Purification of Bergamottin from Citrus grandis (L.) Osbeck cv. Yongjiaozixiangyou and Its Antiproliferative Activity and Effect on Glucose Consumption in HepG2 cells. Molecules. 2017; 22(7). https://doi.org/10.3390/molecules22071227 PMID: 28726768

26. Kim SM, Lee EJ, Lee JH, Yang WM, Nam D, Lee JH, et al. Simvastatin in combination with bergamottin potentiates TNF-induced apoptosis through modulation of NF-kappaB signalling pathway in human chronic myelogenous leukaemia. Pharm Biol. 2016; 54(10):2050–60. https://doi.org/10.3109/13880209.2016.1141221 PMID: 26911804

27. Cai Y, Baer-Dubowska W, Ashwood-Smith M, DiGiovanni J. Inhibitory effects of naturally occurring coumarins on the metabolic activation of benzo[a]pyrene and 7,12-dimethylbenz[a]anthracene in cultured mouse keratinocytes. Carcinogenesis. 1997; 18(1):215–22. https://doi.org/10.1093/carcin/18.1.215 PMID: 9054609
28. Ko JH, Nam D, Um JY, Jung SH, Sethi G, Ahn KS. Bergamottin Suppresses Metastasis of Lung Cancer Cells through Abrogation of Diverse Oncogenic Signaling Cascades and Epithelial-to-Mesenchymal Transition. Molecules. 2018; 23(7). https://doi.org/10.3390/molecules23071601 PMID: 30004418

29. Hwang YP, Yun HJ, Choi JH, Kang KW, Jeong HG. Suppression of phorbol-12-myristate-13-acetate-induced tumor cell invasion by bergamottin via the inhibition of protein kinase Cdelta/p38 mitogen-activated protein kinase and JNK/nuclear factor-kappaB-dependent matrix metalloproteinase-9 expression. Mol Nutr Food Res. 2010; 54(7):977–90. https://doi.org/10.1002/mnfr.200902083 PMID: 19943262

30. Sekiguchi H, Washida K, Murakami A. Suppressive Effects of Selected Food Phytochemicals on CD74 Expression in NCI-N87 Gastric Carcinoma Cells. J Clin Biochem Nutr. 2008; 43(2):109–17. https://doi.org/10.3164/jcbn.2008054 PMID: 18817444

31. Kleiner HE, Reed MJ, DiGiovanni J. Naturally occurring coumarins inhibit human cytochromes P450 and block benzo[a]pyrene and 7,12-dimethylbenz[a]anthracene DNA adduct formation in MCF-7 cells. Chem Res Toxicol. 2003; 16(3):415–22. https://doi.org/10.1021/tr025636d PMID: 12641443

32. Navarre M, Ferlazzo N, Cirmi S, Trappasto E, Bramanti P, Lombardo GE, et al. Effects of bergamot essential oil and its extractive fractions on SH-SY5Y human neuroblastoma cell growth. J Pharm Pharmacol. 2015; 67(8):1042–53. https://doi.org/10.1111/jphp.12403 PMID: 25808679

33. Bart AG, Scott EE. Structures of human cytochrome P450 1A1 with bergamottin and erlotinib reveal active-site modifications for binding of diverse ligands. J Biol Chem. 2018; 293(50):19201–10. https://doi.org/10.1074/jbc.RA118.005588 PMID: 30254074

34. Olguin-Reyes S, Camacho-Carranza R, Hernandez-Ojeda S, Elinos-Baez M, Espinosa-Aguirre JJ. Bergamottin is a competitive inhibitor of CYP1A1 and is antimutagenic in the Ames test. Food Chem Toxicol. 2012; 50(9):3094–9. https://doi.org/10.1016/j.fct.2012.05.058 PMID: 22705772

35. Nishimura M, Yagitli H, Yoshitsugu H, Naito S, Satoh T. Tissue distribution of mRNA expression of human cytochrome P450 450 isoforms assessed by high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi. 2003; 123(5):369–75. https://doi.org/10.1248/yakushi.123.369 PMID: 12772594

36. Sterling KM, Jr., Cutroneo KR. Constitutive and inducible expression of cytochromes P450 401A (CYP1A1 and CYP1A2) in normal prostate and prostate cancer cells. J Cell Biochem. 2004; 91(2):423–9. https://doi.org/10.1002/jcb.10753 PMID: 14743400

37. Girenavar B, Poulose SM, Jayaprakashas GK, Bhat NG, Patil BS. Furocoumarins from grapefruit juice and their effect on human CYP 3A4 and CYP 1B1 isoenzymes. Bioorg Med Chem. 2006; 14(8):2606–12. https://doi.org/10.1016/j.bmc.2005.11.039 PMID: 16338240

38. Jia L, Choong CS, Ricciardelli C, Kim J, Tilley WD, Coetzee GA. Androgen receptor signaling: mechanism of interleukin-6 inhibition. Cancer Res. 2004; 64(7):2619–26. https://doi.org/10.1158/0008-5472.can-03-3486 PMID: 15059919

39. Bower JJ, Vance LD, Psioda M, Smith-Roe SL, Simpson DA, Ibrahim JG, et al. Patterns of cell cycle checkpoint deregulation associated with intrinsic molecular subtypes of human breast cancer cells. NPJ Breast Cancer. 2017; 3:8. https://doi.org/10.1038/s41523-017-0009-7 PMID: 28469449

40. Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. Nature. 2004; 432(7015):316–23. https://doi.org/10.1038/nature03097 PMID: 15549093

41. Barnum KJ, O’Connell MJ. Cell cycle regulation by checkpoints. Methods Mol Biol. 2014; 1124(pr.56.2):159. https://doi.org/10.1007/978-1-4939-0888-2_2 PMID: 24906307

42. Chaitanya GV, Steven AJ, Babu PP. PARP-1 cleavage fragments: signatures of cell-death proteases in neurodegeneration. Cell Commun Signal. 2010; 8:31. https://doi.org/10.1186/1478-811X-8-31 PMID: 21176168

43. Gaston KE, Kim D, Singh S, Ford OH, 3rd, Mohler JL. Racial differences in androgen receptor protein expression in men with clinically localized prostate cancer. J Urol. 2003; 170(3):990–3. https://doi.org/10.1016/j.jv.2018.04.058 PMID: 12913756

44. Wang BD, Yang Q, Cenincoca K, Bianco F, Andrawis R, Jarrett T, et al. Androgen receptor-target genes in african american prostate cancer disparities. Prostate Cancer. 2013; 2013:763569. https://doi.org/10.1155/2013/763569 PMID: 23665759

45. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet. 2001; 27(4):383–91. https://doi.org/10.1038/66882 PMID: 11279519

46. Jatinder Lamba JMH, Erin G. Schuetz, Teri E. Kleinh, and Russ B. Altman. PharmGKB summary: very important pharmacogene information for CYP3A5. Computer. 2008; 144:724–32.

47. Schuetz EG, Relling MV, Kishi S, Wang W, Das S, Chen P, et al. PharmGKB update: II. CYP3A5, cytochrome P450, family 3, subfamily A, polypeptide 5. Pharmacol Rev. 2004; 56(2):159. https://doi.org/10.1124/pr.56.2.1 PMID: 15169924